Investment Banking

Recent News

  • Feb 15, 2010
    Caris & Company appoints Paul Choi Senior Vice...
    Read More
  • Jan 25, 2010
    Caris & Company appoints Ann Hynes Managing Director...
    Read More
  • Dec 8, 2009
    Caris & Company acts as Co-Placement agent for...
    Read More
  • Nov 2, 2009
    Caris & Company appoints Matt Winer Managing Director...
    Read More

Recent Transactions

Caris & Company is proud to announce participation in the following transactions:


  1. $149,000,000

    Syntiron

    Licensing Advisory

    December 16th, 2009

  2. $13,200,000

    Wilex

    Private Placement

    Joint Lead Manager

    December 3rd, 2009

  3. $5,500,000

    PharmAthene

    Registered Direct

    Co-placement Agent

    March 24th, 2009

  4. $160,000,000

    Healthcare Technology

    M&A Buy Side

    Advisor

    February 15th, 2009

  5. $50,000,000

    Medical Diagnostics

    M&A Sell Side

    Advisor

    August 15th, 2008

  6. $12,500,000

    Underground Solutions

    Common Stock

    Financial Advisor

    December 17th, 2007

  7. $21,000,000

    Response Genetics

    IPO

    Co-Manager

    June 5th, 2007

  8. $96,427,500

    Omnicell

    Common Stock

    Co-Manager

    May 22nd, 2007

  9. $17,000,000

    ResVerlogix

    Senior Secured Convertible Notes

    Co-Manager

    January 5th, 2007

  10. $10,000,000

    Cardax

    Series B Preferred Stock

    January 1st, 2007

  11. $56,940,000

    Nextest

    Common Stock

    Initial Public Offering

    March 21st, 2006

  12. $24,000,000

    SGX

    Common Stock

    Initial Public Offering

    January 31st, 2006

  13. $567,168,000

    Spansion

    Common Stock

    Initial Public Offering

    December 16th, 2005

  14. $21,250,000

    Vivus

    Common Stock

    Follow On Offering

    March 10th, 2005

  15. $79,350,000

    Cypress

    Common Stock

    Follow On Offering

    April 2nd, 2004

  16. $110,400,000

    Corgentech

    Common Stock

    Initial Public Offering

    February 12th, 2004

  17. $64,000,000

    Esperion Therapeutics

    Common Stock

    Follow On Offering

    July 31st, 2003